Recent Tweets

Recent Tweets


Reviewing IFF’s $7 Billion Acquisition of Frutarom

Many companies grow through acquisitions, but Wall Street is often skeptical of big deals given the risks involved. In May 2018, International Flavors & Fragrances (IFF) announced it was buying rival Frutarom in a $7.1 billion cash-and-stock deal. Given that IFF's market cap at the time was just over $12 billion, this qualified as a big acquisition. [...]

February 12th, 2019|Uncategorized|

Johnson & Johnson: A Dependable Dividend King for the Long Term

Founded in 1885, Johnson & Johnson (JNJ) is the world’s largest medical conglomerate. With more than 250 subsidiaries operating in over 60 countries, Johnson & Johnson’s three major business units provide it with a diversified mix of revenue, earnings, and cash flow. Here are the company’s operating segments: Pharmaceuticals (50% of sales, 61% of pretax [...]

February 12th, 2019|Uncategorized|

Pfizer: One of the Best Dividend Stocks in Pharma

Founded in 1849, Pfizer (PFE) is one of the world's largest drugmakers, with medications sold in over 125 countries. The company's annual sales exceed $50 billion and are grouped into three business segments: Pfizer Biopharmaceuticals (56% of sales): produces patented medicines to treat various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare [...]

February 8th, 2019|Uncategorized|

Top 10 Recession Proof Dividend Aristocrats

Many investors desire to live off safe and growing dividends during retirement, allowing them to worry less about stock market fluctuations and recessions. To this end, many blue-chip dividend stocks have impressive track records of not only maintaining or growing their payouts during market downturns, but also outperforming the broader market. Dividend aristocrats, S&P 500 companies [...]

February 7th, 2019|Uncategorized|

Gilead’s Dividend is Solid, But Growth Challenges Linger

Founded in 1987, Gilead Sciences (GILD) is one of the world's leading biotech companies. The firm operates in more than 35 countries worldwide, researching, manufacturing, and distributing various medications to treat HIV/AIDs, liver diseases, and immune, respiratory, and cardiovascular diseases. Gilead has historically focused on antiviral products for infectious diseases, which made up 84% of [...]

February 6th, 2019|Uncategorized|

AbbVie’s Long-term Outlook Remains Volatile

AbbVie (ABBV) was spun off from Abbott Laboratories (ABT) in 2013 as a standalone biopharmaceutical company focused on four primary therapeutic areas: immunology, oncology, virology, and neuroscience. The company's drugs treat conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology; oncology, including blood cancers; virology, including hepatitis C (HCV) and human immunodeficiency virus [...]

February 6th, 2019|Uncategorized|

Cardinal Health’s Dividend Safety

Cardinal Health's (CAH) stock price has slumped nearly 40% over the last two years, driving its dividend yield to a record high of 4.4% in late 2018. Dividend aristocrats such as Cardinal Health are often owned under the assumption that they will generate safe, growing income while recording healthy total returns and low stock price volatility [...]

February 5th, 2019|Uncategorized|

National Retail: Higher Dividends for 29 Straight Years

Founded in 1984, National Retail Properties (NNN) is one of America's oldest triple net lease, or NNN, REITs. The company follows a "sale-leaseback" model in which it will buy a property from an existing tenant and then rent the property back to the former owner under long-term (15 to 20-year) contracts. The average remaining lease [...]

February 4th, 2019|Uncategorized|

Altria Prepares for Evolving Tobacco Market

Founded in 1919 in Richmond, Virginia, Altria (MO) is America’s largest tobacco company. The business split into three separate firms in 2007 and 2008 (Altria, Phillip Morris International, and Kraft), with Altria retaining all domestic tobacco operations. Altria has exclusive U.S. rights to sell cigarettes primarily under the Marlboro, Parliament, Virginia Slims, and Benson & [...]

February 4th, 2019|Uncategorized|